ELVN — Enliven Therapeutics Share Price
0.000.00%
Last trade - 00:00- $892.37m
- $578.93m
- 43
- 25
- 80
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.88 | ||
| Price to Tang. Book | 2.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -33.74% | ||
| Return on Equity | -32.04% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 0.01 | 0.01 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Directors
- David Mott NEC (55)
- Rahul Ballal PRE (43)
- Michael Gray CFO (50)
- Kenneth Attie SVP (64)
- Lynette Hopkinson SVP
- David Bonita IND (45)
- Mark Chin IND (39)
- Edward Conner IND (48)
- Barbara Dalton IND (66)
- Carl Goldfischer IND (62)
- Laura Williams IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 26th, 2016
- Public Since
- March 12th, 2020
- No. of Shareholders
- 20
- No. of Employees
- 62
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 49,004,425
- Address
- 6200 Lookout Road, BOULDER, 80301
- Web
- https://www.enliventherapeutics.com/
- Phone
- +1 7206478519
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ELVN
Enliven Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Enliven Therapeutics Inc Earnings Release
Similar to ELVN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Enliven Therapeutics share price?
As of Today at 20:27 UTC, shares in Enliven Therapeutics are trading at $18.21. This share price information is delayed by 15 minutes.
How has the Enliven Therapeutics share price performed this year?
Shares in Enliven Therapeutics last closed at $18.21 and the price had moved by +8.52% over the past 365 days. In terms of relative price strength the Enliven Therapeutics share price has outperformed the S&P500 Index by +0.17% over the past year.
What are the analyst and broker recommendations for Enliven Therapeutics?
The overall consensus recommendation for Enliven Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Enliven Therapeutics dividend yield?
Enliven Therapeutics does not currently pay a dividend.
Does Enliven Therapeutics pay a dividend?
Enliven Therapeutics does not currently pay a dividend.
When does Enliven Therapeutics next pay dividends?
Enliven Therapeutics does not currently pay a dividend.
How do I buy Enliven Therapeutics shares?
To buy shares in Enliven Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Enliven Therapeutics?
As of the previous close price of $18.21, shares in Enliven Therapeutics had a market capitalisation of $892.37m.
Where are Enliven Therapeutics shares listed?
Here are the trading details for Enliven Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ELVN
What kind of share is Enliven Therapeutics?
Based on an overall assessment of its quality, value and momentum Enliven Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Enliven Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Enliven Therapeutics is $38.14. That is 109.45% above the last closing price of $18.21.
Analysts covering Enliven Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.22 for the next financial year.
Find out moreWhat is the trend in the Enliven Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Enliven Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -33.38%.
As of the last closing price of $18.21, shares in Enliven Therapeutics were trading -21.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Enliven Therapeutics PE Ratio?
The Enliven Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Enliven Therapeutics?
Enliven Therapeutics' management team is headed by:
- David Mott - NEC
- Rahul Ballal - PRE
- Michael Gray - CFO
- Kenneth Attie - SVP
- Lynette Hopkinson - SVP
- David Bonita - IND
- Mark Chin - IND
- Edward Conner - IND
- Barbara Dalton - IND
- Carl Goldfischer - IND
- Laura Williams - IND